Can Humans Live to 150? Longevity Research Hype vs. Reality

A new Nature analysis claims human lifespan could reach 150 years via anti-aging drugs, but the evidence is still preliminary. While promising, the breakthrough raises ethical and access issues, especially for aging populations in the Nordics and globally.

**1. THE NEWS**

A new analysis published in Nature, reported by Longevity Drugs, suggests that the biological limit of human lifespan may be 150 years. Researchers claim that drugs and gene therapies slowing the aging process are bringing this goal within reach. Senolytic drugs (which clear senescent cells) and telomere-lengthening treatments have extended lifespan by up to 30% in mouse trials. Human trials are slated to begin in 2025.

**2. WHY IT MATTERS**

This claim is potentially transformative for global aging populations. The WHO projects that by 2050, the number of people aged 60+ will reach 2.1 billion. In Sweden, 20% of the population is already over 65. Longevity technologies could increase healthy lifespan, reducing healthcare costs and reshaping pension systems. However, unequal access may exacerbate social divides, as wealthy nations and individuals adopt treatments first.

**3. CONTEXT & EXAMPLES**

Life expectancy has risen steadily: from 31 years in 1900 to 73 in 2023. But maximum lifespan has plateaued at 122 years since the 1960s. The new paradigm treats aging as a disease. For instance, Unity Biotechnology's senolytic drug showed promise in Phase II osteoarthritis trials. At Karolinska Institute in Sweden, researchers are working on epigenetic reprogramming to reverse cellular age. The global anti-aging market was $60 billion in 2020, projected to exceed $100 billion by 2030. Critics argue that 150 is an exaggeration; without curing cancer or Alzheimer's, such longevity is unlikely. A 2021 study in Nature Communications found that human lifespan has a hard limit around 120-150 years based on loss of resilience.

**4. FORWARD LOOK**

The next decade may see the first anti-aging drugs approved. But ethical debates will intensify: Who gets access? How will governments manage budgets? Nordic countries with strong welfare states may need to adapt pension ages and healthcare models. Regulatory bodies like the FDA and EMA are still reluctant to recognize aging as an indication. The 150-year claim remains controversial, but the pursuit of healthy aging is a legitimate scientific frontier. Watch for human trial results from companies like Altos Labs and Calico, and for policy shifts in aging research funding.